Human medicines European public assessment report (EPAR): Vazkepa, icosapent ethyl, Dyslipidemias, Date of authorisation: 26/03/2021, Revision: 5, Status: Authorised
Vazkepa is a medicine for reducing the risk of cardiovascular events such as heart attack, stroke and other problems caused by blocked blood circulation. It is for use as add-on treatment in adults being treated with a statin medicine who have high levels of triglycerides (a type of fat) in their blood.
Vazkepa is to be used in patients either with a cardiovascular disease (a condition that affects the heart or circulation) or with diabetes and another condition that increases the risk of cardiovascular events.
Vazkepa contains the active substance icosapent ethyl.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
